PROTAC BET Degrader-15

PROTAC BET Degrader-15 是一种 BET PROTAC 降解剂,对 BRD2、BRD3 和 BRD4 的 DC50 分别为 <0.10 nM、<0.01 nM 和 <0.01 nM,可诱导显著的 G2/M 期细胞周期阻滞和细胞凋亡 (apoptosis),导致 c-Myc 显著下调,并伴随细胞周期抑制蛋白 p21 上调、CDK6 下调和凋亡标志物 cleaved PARP 增加,可用于血液系统恶性肿瘤和肺癌的研究(粉色:BRD2 和 BRD3 和 BRD4 配体 (MS-T85952);蓝色:Cereblon 配体 (MS-V29738);黑色:连接子 (MS-R64227))。
PROTAC BET Degrader-15
产品编号: MS-R32937 分子式: C44H45N9O6 分子量: 795.88
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

PROTAC BET Degrader-15 是一种 BET PROTAC 降解剂,对 BRD2、BRD3 和 BRD4 的 DC50 分别为 <0.10 nM、<0.01 nM 和 <0.01 nM,可诱导显著的 G2/M 期细胞周期阻滞和细胞凋亡 (apoptosis),导致 c-Myc 显著下调,并伴随细胞周期抑制蛋白 p21 上调、CDK6 下调和凋亡标志物 cleaved PARP 增加,可用于血液系统恶性肿瘤和肺癌的研究(粉色:BRD2 和 BRD3 和 BRD4 配体 (MS-T85952);蓝色:Cereblon 配体 (MS-V29738);黑色:连接子 (MS-R64227))。

生物实验数据

生物活性 PROTAC BET Degrader-15 is a BET PROTAC degrader with DC50 values of <0.10 nM, <0.01 nM, and <0.01 nM for BRD2, BRD3, and BRD4, respectively; it induces pronounced G2/M cell cycle arrest and apoptosis, causes significant downregulation of c-Myc accompanied by upregulation of the cell cycle inhibitory protein p21, downregulation of CDK6, and an increase in the apoptosis marker cleaved PARP, and can be used for research on hematological malignancies and lung cancer (pink: BRD2 and BRD3 and BRD4 ligand (MS-T85952); blue: Cereblon ligand (MS-V29738); black: linker (MS-R64227)).
IC50 & Target

BRD2

<0.10 nM (DC50)

BRD3

<0.01 nM (DC50)

BRD4

<0.01 nM (DC50)

CDK6

 

体外研究
(In Vitro)

PROTAC BET Degrader-15 (Compound CR10) (72 h) 可强效抑制 MV4-11、Molm-13 和 HL-60 急性髓系白血病细胞的增殖,其 IC50 值分别为 1.21、2.14 和 0.69 nM。
PROTAC BET Degrader-15 (72 h) 可强效抑制多种实体肿瘤细胞系的增殖,其 IC50 值范围为 2.83 nM (MDA-MB-231) 至 254.2 nM (A549)。
PROTAC BET Degrader-15 (5-20 nM; 2 h) 可通过依赖 CRBN 和 BET 蛋白结合的泛素-蛋白酶体系统依赖性机制,在 MV4-11 和 A549 细胞中诱导 BRD2、BRD3 和 BRD4 降解。
PROTAC BET Degrader-15 (1 h) 以纳摩尔亲和力结合 BRD2、BRD3 和 BRD4 溴结构域,其 IC50 值范围为 22 nM (BRD3 (1)) 至 61 nM (BRD4 (2))。
PROTAC BET Degrader-15 (1-50 nM; 24 h) 以剂量依赖的方式将 MV4-11 细胞阻滞于细胞周期的 G2/M 期。
PROTAC BET Degrader-15 (1-20 nM; 24 h) 可剂量依赖性地诱导 MV4-11 细胞发生细胞凋亡,在处理 24 h 后,低至 1 nM 的浓度下即可观察到显著的细胞凋亡。
PROTAC BET Degrader-15 (3.3-1000 nM; 24 h) 可调控 MV4-11、A549 和 MDA-MB-231 细胞中与增殖、细胞周期调控及凋亡相关的关键蛋白,包括下调 C-Myc 和 CDK6、上调 P21 并诱导 PARP 切割。
PROTAC BET Degrader-15 (4-50 nM; 8 d) 可强效抑制 A549 和 MDA-MB-231 实体瘤细胞的集落形成能力,在 10 nM 浓度下可观察到近乎完全的抑制作用。
PROTAC BET Degrader-15 (50-100 nM; 0-12 h) 可在 50 nM 和 100 nM 浓度下强效抑制 MDA-MB-231 乳腺癌细胞的迁移能力。

Western Blot Analysis

Cell Line: MV4-11 and A549 cells
Concentration: 5 nM (MV4-11 cells, 2 h); 20 nM (A549 cells, 2 h); 10 μM MG132, 10 μM Pomalidomide, 10 μM MLN4924, 100 nM compound 10 (2 h pretreatment)
Incubation Time: 2 h (PROTAC BET Degrader-15 treatment); 2 h (pretreatment prior to PROTAC BET Degrader-15 addition)
Result: Had induced degradation of BRD2, BRD3, and BRD4 completely abolished by pretreatment with MG132, Pomalidomide, MLN4924, or compound 10 in both MV4-11 and A549 cells.

Cell Cycle Analysis

Cell Line: MV4-11 cells
Concentration: 1, 5, 20 and 50 nM
Incubation Time: 24 h
Result: Induced a significant, dose-dependent arrest at the G2/M phase of the cell cycle.

Apoptosis Analysis

Cell Line: MV4-11 cells
Concentration: 1, 5 and 20 nM
Incubation Time: 24 h
Result: Elicited pronounced pro-apoptotic effects starting at 1 nM, with apoptosis increasing in a dose-dependent manner.

Western Blot Analysis

Cell Line: MV4-11, A549, and MDA-MB-231 cells
Concentration: 3.3, 10, 100, 200 and 1000 nM
Incubation Time: 24 h
Result: Caused dose-dependent downregulation of C-Myc and CDK6, upregulation of P21, and an increase in cleaved-PARP levels (with a corresponding decrease in full-length PARP) in all three cell lines.

Cell Migration Assay

Cell Line: MDA-MB-231 breast cancer cells
Concentration: 50 and 100 nM
Incubation Time: 0, 6, 12 h post-treatment monitoring
Result: Significantly suppressed cell migration relative to controls, as measured by reduced wound closure over time.
体内研究
(In Vivo)

PROTAC BET Degrader-15 (Compound CR10) (1-2 mg/kg; i.p.; 每 4 天一次共 21 天) 可在 A549 异种移植小鼠中诱导剂量依赖性的肿瘤生长抑制。
PROTAC BET Degrader-15 (1-2 mg/kg; i.p.; 每 4 天一次共 17 天) 可在 MV4-11 异种移植小鼠中诱导剂量依赖性肿瘤生长抑制。

Animal Model: BALB/c nude (female, 6-8 weeks old)
Dosage: 1 mg/kg; 2 mg/kg
Administration: i.p.; every 4 days; 21 days
Result: Induced tumor growth inhibition rate of 54.74% at 1 mg/kg and 72.97% at 2 mg/kg, which were notably higher than the positive control dBet1.
Maintained largely unchanged body weights throughout the study.
Showed no obvious lesions in major organs (heart, liver, spleen, lung, kidney) via histopathological examination.
Showed no significant abnormalities in hematological and biochemical analyses.
Animal Model: BALB/c nude (female, 6-8 weeks old)
Dosage: 1 mg/kg; 2 mg/kg
Administration: i.p.; every 4 days; 17 days
Result: Induced tumor growth inhibition rates of 44.26% at 1 mg/kg and 63.19% at 2 mg/kg, which were higher than the positive control dBet1.
Maintained largely unchanged body weights throughout the study.
Showed no obvious lesions in major organs (heart, liver, spleen, lung, kidney) via histopathological examination.
Showed no significant abnormalities in hematological and biochemical analyses.

化学信息

分子量 795.88
分子式 C44H45N9O6

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础